Based on these previous findings, the aim of the present study was to investigate the following: (i) whether the PLA2R1 promoter is also hypermethylated in patients with childhood ALL at diagnosis in comparison to healthy individuals; (ii) whether the PLA2R1 promoter methylation in blood leukocyte DNA can be used as a biomarker for treatment response and control of residual disease. This evidence concerns the gene PLA2R1 and acute lymphoblastic leukemia.